• Explore /
  • Poster
  • / Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial.

Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial.

Abstract Poster

Authors

null

Orazio Caffo

Santa Chiara Hospital, Trento, Italy

Orazio Caffo , Michele Aieta , Erica Palesandro , Marianna Macerelli , Claudia Mucciarini , Maurizio Nicodemo , Ugo De Giorgi , Donata Sartori , Lucia Fratino , Roberto Iacovelli , Sabrina Rossetti , Daniela Scapoli , Franco Morelli , Francesco Carrozza , Franco Nole , Vittorina Zagonel , Carlo Messina , Donatello Gasparro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02453009

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 123)

Abstract #

123

Poster Bd #

F3

Abstract Disclosures

Similar Posters

First Author: Mehmet Asim Bilen

First Author: Vincenzo Gennusa

First Author: Shingo Hatakeyama

First Author: Rebeca Lozano